RBD-VLP Vaccines Adjuvanted with Alum or SWE Protect K18-hACE2 Mice against SARS-CoV-2 VOC Challenge-Reference-Cited by-同舟云学术

RBD-VLP Vaccines Adjuvanted with Alum or SWE Protect K18-hACE2 Mice against SARS-CoV-2 VOC Challenge

Published:2022-08-31 Issue:4 Volume:7 Page:
ISSN:2379-5042
Container-title:mSphere
language:en
Short-container-title:mSphere

Author:

Wong Ting Y.¹²,Russ Brynnan P.¹²,Lee Katherine S.¹²,Miller Olivia A.¹²,Kang Jason¹²^ORCID,Cooper Melissa¹²,Winters Michael T.¹,Rodriguez-Aponte Sergio A.³⁴,Dalvie Neil C.⁴⁵,Johnston Ryan S.⁴,Rader Nathaniel A.¹²,Wong Zeriel Y.¹²,Cyphert Holly A.⁶,Martinez Ivan¹⁷⁸,Shaligram Umesh⁹,Batwal Saurabh⁹,Lothe Rakesh⁹,Chandrasekaran Rahul⁹,Nagar Gaurav⁹,Rajurkar Meghraj⁹,Rao Harish⁹,Bevere Justin R.¹²,Barbier Mariette¹²^ORCID,Love J. Christopher⁴⁵^ORCID,Damron F. Heath¹²^ORCID

Affiliation:

1. Department of Microbiology, Immunology, and Cell Biology, West Virginia University, Morgantown, West Virginia, USA

2. Vaccine Development Center at West Virginia University Health Sciences Center, Morgantown, West Virginia, USA

3. Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA

4. The Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA

5. Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA

6. Department of Biological Sciences, Marshall University, Huntington, West Virginia, USA

7. West Virginia University Cancer Institute, Morgantown, West Virginia, USA

8. School of Medicine, Morgantown, West Virginia, USA

9. Serum Institute of India Pvt. Ltd., Pune, Maharashtra, India

Abstract

Global COVID-19 vaccine distribution to low-income countries has been a major challenge of the pandemic. To address supply chain issues, RBD virus-like particle (VLP) vaccines that are cost-effective and capable of large-scale production were developed and evaluated for efficacy in preclinical mouse studies.

Funder

Serum Institute of India

Publisher

American Society for Microbiology

Subject

Molecular Biology,Microbiology

Link

https://journals.asm.org/doi/pdf/10.1128/msphere.00243-22

Reference75 articles.

1. SARS-CoV-2 variants of concern partially escape humoral but not T cell responses in COVID-19 convalescent donors and vaccine recipients

2. Aleem A, Samad Akbar Bari A, Slenker KA. 2022. Emerging variants of SARS-CoV-2 and novel therapeutics against coronavirus (COVID-19). StatPearls Publishing, Treasure Island, FL.

3. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization

4. SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion

5. Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Influenza virus strains expressing SARS-CoV-2 receptor binding domain protein confer immunity in K18-hACE2 mice;Vaccine: X;2024-10

2. Efficacy of a stable broadly protective subunit vaccine platform against SARS-CoV-2 variants of concern;Vaccine;2024-08

3. A virus-like particle candidate vaccine based on CRISPR/Cas9 gene editing technology elicits broad-spectrum protection against SARS-CoV-2;Antiviral Research;2024-05

4. Efficacy of a stable multivalent broadly protective subunit vaccine platform against SARS-CoV-2 variants of concern;2023-11-28

5. Large-Scale Purification and Characterization of Recombinant Receptor-Binding Domain (RBD) of SARS-CoV-2 Spike Protein Expressed in Yeast;Vaccines;2023-10-16